Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such delivery device
A device for delivering a treatment medium to an eye includes a first body portion configured to be removably inserted and secured in an opening of the eye, and a second body portion supported by the first body portion. At least the second body portion includes a treatment medium, and a coating having an opening through which the treatment medium elutes out of the device.
1. A device for delivering a treatment medium to an eye, comprising:
a biocompatible polymer capsule comprising a core containing a therapeutic medium immobilized with a biocompatible matrix and a surrounding jacket that permits diffusion of the therapeutic medium to the eye; and,
wherein the delivery device is configured and arranged to occlude or plug the punctum.
2. The device of claim 1 , wherein the biocompatible matrix comprises a hydrogel.
3. The device of claim 1 , wherein the biocompatible matrix comprises biodegradable polymers.
4. The device of claim 1 , wherein the jacket is a semi-permeable membrane.
5. The device of claim 1 , wherein the jacket comprises polymers or polymer blends of polyacrylates, acrylic copolymers, polyvinylidenes, polyvinyl chloride copolymers, polyurethanes, polystyrenes, polyamides, cellulose acetates, cellulose nitrates, polysulfones, polyether sulfones, polyphosphazenes, polyacrylonitriles, poly(acrylonitrile/covinyl chloride), or combinations thereof.
6. The device of claim 1 , wherein the treatment medium comprises a prostaglandin, anti-inflammatories, non-steroidal anti-inflammatories or immunosuppressive agents.
7. The device of claim 6 , wherein the treatment medium comprises dexamethasone or a corticosteroid.
8. The device of claim 1 , wherein the treatment medium is selected from the group consisting of thrombin inhibitors; anti-thrombogenic agents; thrombolytic agents; fibrinolytic agents; vasospasm inhibitors; calcium channel blockers; vasodilators; antihypertensive agents; antimicrobial agents; inhibitors of surface glycoprotein receptors; antiplatelet agents; anti-mitotics; microtubule inhibitors; anti-secretory agents; active inhibitors; remodeling inhibitors; antisense nucleotides; anti-metabolites; anti-proliferatives; anticancer chemotherapeutic agents; anti-inflammatories; non-steroidal anti-inflammatories; anti-allergenics; antiproliferative agents; decongestants; miotics, anticholinesterase; anti-neoplastics; immunological drugs; hormonal agents; immunosuppressive agents; growth hormone antagonists; growth factors; inhibitors of angiogenesis; dopamine agonists; radiotherapeutic agents; peptides; proteins; enzymes; extracellular matrix components; ACE inhibitors; free radical scavengers; chelators; antioxidants; anti-polymerases; photodynamic therapy agents; gene therapy agents; prostaglandins; anti-prostaglandins; prostaglandin precursors and combinations thereof.
9. The device of claim 1 , wherein the treatment medium is delivered in a controllable manner over a predetermined time period directly to the eye.
10. The device of claim 1 , wherein the treatment medium is retained in proximity to the external surface of the eye and is prevented from leaving the treatment site via the blocked punctum.
11. A method for delivering a treatment medium to an eye, comprising:
providing a delivery device according to claim 1 comprising a treatment medium; and
inserting the delivery device into a punctum of the eye, whereby the treatment medium is delivered to the eye.
12. The method of claim 11 , wherein the treatment medium is formulated as a sustained release formulation.
13. The method of claim 11 , wherein the treatment medium is a treatment for pre- and post-operative inflammation or pain, glaucoma, inflammation, infections, or dry eye.